Mercaptopurine - Warnings and Precautions
The following warnings and precautions are taken directly from the US FDA-approved drug label for Mercaptopurine. This is the same information dispensing pharmacists read.
5 WARNINGS AND PRECAUTIONS • Myelosuppression : Monitor complete blood count (CBC) and adjust the dose of mercaptopurine for excessive myelosuppression.
Consider testing in patients with severe myelosuppression or repeated episodes of myelosuppression for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency.
Patients with homozygous-TPMT or homozygous-NUDT15 deficiency may require a dose reduction. ( 2.2 , 5.1 ) • Hepatotoxicity : Monitor transaminases, alkaline phosphatase and bilirubin.
Withhold mercaptopurine at onset of hepatotoxicity. • Immunosuppression : Response to all vaccines may be diminished and there is a risk of infection with live virus vaccines.
Consult immunization guidelines for immunocompromised pediatrics. • Treatment Related Malignancies : Aggressive and fatal cases of hepatosplenic T-cell lymphoma have occurred. • Macrophage Activation Syndrome : Monitor for and treat promptly; discontinue mercaptopurine. • Embryo-Fetal Toxicity : Can cause fetal harm.
Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.6 , 8.1 , 8.3 ) • Phenylketonuria : Patients should be informed that mercaptopurine oral suspension contains phenylalanine, a component of aspartame.
Each mL of the 20 mg/mL oral suspension contains 0.015 mg of phenylalanine.
5.1 Myelosuppression The most consistent, dose-related adverse reaction of mercaptopurine is myelosuppression, manifested by anemia, leukopenia, thrombocytopenia, or any combination of these.
Monitor CBC and adjust the dosage of mercaptopurine for excessive myelosuppression [see Dosage and Administration ] .
Consider testing for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency in patients with severe myelosuppression or repeated episodes of myelosuppression.
TPMT genotyping or phenotyping (red blood cell TPMT activity) and NUDT15 genotyping can identify patients who have reduced activity of these enzymes.
Patients with homozygous TPMT or NUDT15 deficiency may require a dose reduction [see Dosage and Administration , Clinical Pharmacology ] .
Myelosuppression can be exacerbated by coadministration with allopurinol, aminosalicylates or other products that cause myelosuppression [see Drug Interactions ( 7.1 , 7.3 , 7.4 )] .
Reduce the dosage of mercaptopurine when coadministered with allopurinol [see Dosage and Administration ] .
5.2 Hepatotoxicity Mercaptopurine is hepatotoxic.
There are reports of deaths attributed to hepatic necrosis associated with the administration of mercaptopurine.
Hepatic injury can occur with any dosage but seems to occur with greater frequency when the recommended dosage is exceeded.
In some patients, jaundice has cleared following withdrawal of mercaptopurine and reappeared with rechallenge.
Usually, clinically detectable jaundice appears early in the course of treatment (1 to 2 months); however, jaundice has been reported as early as 1 week and as late as 8 years after starting mercaptopurine.
The hepatotoxicity has been associated in some cases with anorexia, diarrhea, jaundice, ascites, and pruritus.
Hepatic encephalopathy has occurred.
Monitor serum transaminase levels, alkaline phosphatase, and bilirubin levels at weekly intervals when first beginning therapy and at monthly intervals thereafter.
Monitor liver tests more frequently in patients who are receiving mercaptopurine with other hepatotoxic drugs [see Drug Interactions ] or with known pre-existing liver disease.
Withhold mercaptopurine at onset of hepatotoxicity.
Intrahepatic Cholestasis of Pregnancy Postmarketing cases of intrahepatic cholestasis of pregnancy (ICP) have been reported in patients with inflammatory bowel disease who received mercaptopurine during pregnancy.
Applies to YOU?
Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 49+ warnings apply to your profile.
Ask Health AI \u2192